Avanos Medical, Inc. to Present at the 2026 Citizens Life Sciences Conference

Rhea-AI Summary

Avanos Medical (NYSE: AVNS) will present at the 2026 Citizens Life Sciences Conference on March 11, 2026. CEO Dave Pacitti and CFO Scott Galovan will appear in a fireside chat at ~1:05 p.m. ET.

A live webcast will be available and later archived on the company's Investors webpage.

News Market Reaction – AVNS

+0.07%

+0.07% Session close to close

In the Mar 3 session, AVNS gained 0.07%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Avanos’ participation in the 2026 Citizens Life Sciences Conference, wh...

Analysis

This announcement highlights Avanos’ participation in the 2026 Citizens Life Sciences Conference, where leadership will join a fireside chat on March 11 at 1:05 p.m. ET. It extends a recent pattern of investor outreach following earnings, governance updates, and strategic partnerships. Investors may watch for any qualitative commentary on transformation efforts, cost savings targets, and portfolio strategy that could clarify or build on disclosures in recent 10-K and 8-K filings.

Key Figures

Conference date: March 11, 2026 Presentation time: 1:05 p.m. ET

2 metrics

Conference date March 11, 2026 Citizens Life Sciences Conference appearance

Presentation time 1:05 p.m. ET Scheduled fireside chat start time

Historical Context

5 past events · Latest: Feb 26 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 26	Board nominations	Neutral	+0.9%	Cooperation agreement and nomination of two independent directors.
Feb 24	Earnings results	Negative	-10.4%	2025 results with goodwill impairment and weaker adjusted profitability.
Feb 16	Earnings call setup	Neutral	+0.1%	Announcement of webcasted call to discuss Q4 and full‑year 2025.
Feb 03	Reimbursement update	Positive	-0.4%	CMS maintained NOPAIN Act payments and added Game Ready in 2026.
Jan 20	Strategic partnership	Positive	+0.1%	Co‑marketing agreement with Siemens Healthineers for pain management.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

News-driven moves have mostly aligned with sentiment, with a notable negative reaction to earnings and one divergence on favorable CMS reimbursement.

Recent Company History

In the last few months, Avanos announced board refresh actions and a cooperation agreement with investor Bradley Radoff (Feb 26, 2026), modest 2025 financial results with a $77.0M goodwill impairment (Feb 24, 2026), and scheduled its earnings call on Feb 16, 2026. Earlier, CMS maintained NOPAIN Act payment and expanded device eligibility (Feb 3, 2026), and Avanos entered a strategic co‑marketing collaboration with Siemens Healthineers (Jan 20, 2026). Today’s conference appearance continues this pattern of investor- and clinician-facing communications.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ALPHARETTA, Ga., March 2, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Dave Pacitti, chief executive officer, and Scott Galovan, senior vice president and chief financial officer, will participate in a fireside chat at the 2026 Citizens Life Sciences Conference on Wed., March 11 at approximately 1:05 p.m. Eastern Time.

A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site.

About Avanos Medical, Inc.

Avanos Medical, Inc. (NYSE: AVNS) is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to what matters. Headquartered in Alpharetta, Georgia, we are committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. We develop, manufacture and market our recognized brands globally and hold leading market positions in multiple categories across our portfolio. For more information, visit avanos.com and follow Avanos Medical on X (@AvanosMedical), LinkedIn and Facebook.

View original content to download multimedia:https://www.prnewswire.com/news-releases/avanos-medical-inc-to-present-at-the-2026-citizens-life-sciences-conference-302701642.html

SOURCE Avanos Medical

FAQ

When will Avanos Medical (AVNS) present at the 2026 Citizens Life Sciences Conference?

Avanos will present on March 11, 2026 at approximately 1:05 p.m. ET. According to the company, CEO Dave Pacitti and CFO Scott Galovan will participate in a fireside chat and answer investor questions during the session.

Who from Avanos Medical (AVNS) will speak at the March 11, 2026 conference?

CEO Dave Pacitti and SVP/CFO Scott Galovan will speak in the fireside chat. According to the company, both executives will discuss strategy and financial topics during the approximate 1:05 p.m. ET presentation slot.

How can investors watch the Avanos Medical (AVNS) presentation on March 11, 2026?

A live webcast will be available on Avanos' Investors website for the March 11 presentation. According to the company, the webcast will also be archived on the same investor page for later viewing.

Will the Avanos Medical (AVNS) March 11, 2026 webcast be archived for later access?

Yes, the webcast will be archived on the company's Investors webpage after the event. According to the company, investors can access the archived presentation for on-demand viewing following the conference.

What topics will Avanos Medical (AVNS) executives likely cover in the March 11, 2026 fireside chat?

The fireside chat will likely cover company strategy and financial outlook as presented by CEO and CFO. According to the company, the session is intended to provide investor-focused updates and executive perspectives during the conference.